Asthma breakthrough: could new drug let patients drop other meds?

NCT ID NCT06465485

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing if a drug called benralizumab can help people with severe eosinophilic asthma safely reduce their other daily asthma controller medications. About 504 patients in China will receive benralizumab and then try to step down their other treatments over 24 weeks. The main goal is to see how many patients can successfully reduce their medication burden while keeping their asthma under control.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Research Site

Beijing, 100020, China
Research Site

Beijing, 100029, China
Research Site

Beijing, 100191, China
Research Site

Beijing, 100730, China
Research Site

Changsha, 410005, China
Research Site

Changsha, 410008, China
Research Site

Changsha, 410011, China
Research Site

Chengdu, 610014, China
Research Site

Chengdu, 610021, China
Research Site

Chengdu, 610041, China
Research Site

Chengdu, 610072, China
Research Site

Chongqing, 402260, China
Research Site

Guangzhou, 510163, China
Research Site

Guangzhou, 510280, China
Research Site

Guangzhou, 510515, China
Research Site

Guangzhou, 510630, China
Research Site

Guilin, 541001, China
Research Site

Guiyang, 510630, China
Research Site

Hangzhou, 310006, China
Research Site

Hangzhou, 310009, China
Research Site

Hefei, 230061, China
Research Site

Hefei, 230601, China
Research Site

Hohhot, 010010, China
Research Site

Hohhot, 10050, China
Research Site

Huzhou, 313003, China
Research Site

Jinan, 250012, China
Research Site

Jinan, 250014, China
Research Site

Jinan, 250030, China
Research Site

Kunming, CN-650034, China
Research Site

Lanzhou, 730000, China
Research Site

Luoyang, 471000, China
Research Site

Nanjing, 210029, China
Research Site

Nanjing, 211100, China
Research Site

Nanning, 530021, China
Research Site

Ningbo, 315010, China
Research Site

Qingdao, 266042, China
Research Site

Shanghai, 200025, China
Research Site

Shanghai, 200032, China
Research Site

Shanghai, 200065, China
Research Site

Shanghai, 200080, China
Research Site

Shanghai, 200092, China
Research Site

Shenyang, 110004, China
Research Site

Shenyang, China
Research Site

Shenzhen, 518001, China
Research Site

Shenzhen, 518036, China
Research Site

Shenzhen, 518039, China
Research Site

Shenzhen, 518101, China
Research Site

Shijiazhuang, 054001, China
Research Site

Shijiazhuang, 50051, China
Research Site

Suzhou, 215004, China
Research Site

Suzhou, 215006, China
Research Site

Taiyuan, 030001, China
Research Site

Taiyuan, 030032, China
Research Site

Tangshan, 63000, China
Research Site

Tianjin, 300050, China
Research Site

Tianjin, 300192, China
Research Site

Tianjin, 300222, China
Research Site

Weifang, 261000, China
Research Site

Wenzhou, 325000, China
Research Site

Wuhan, 430010, China
Research Site

Wuhan, 430022, China
Research Site

Wuhan, 430060, China
Research Site

Wuhu, 241000, China
Research Site

Xi'an, 710061, China
Research Site

Xi'an, 710068, China
Research Site

Xi'an, 710100, China
Research Site

Xiamen, 361004, China
Research Site

Xinxiang, 453100, China
Research Site

Xuzhou, 221009, China
Research Site

Yangzhou, 225001, China
Research Site

Zhangzhou, 363099, China
Research Site

Zhengzhou, 450003, China
Research Site

Zhengzhou, 450007, China
Research Site

Zhengzhou, 450052, China

Conditions

Explore the condition pages connected to this study.

SEVERE EOSINOPHILIC ASTHMA